Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression

Background Although arsenic trioxide (ATO) is used in the treatment of advanced hepatocellular carcinoma (HCC) in clinical trials, it is not satisfactory in terms of improving HCC patients’ overall survival. Intratumoral hypoxia and overexpression of hypoxia-inducible factor-1α (HIF-1α) may result i...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Digestive diseases and sciences 2022-08, Vol.67 (8), p.3806-3816
Hauptverfasser:	Chen, Yaoting, Li, Huiqing, Chen, Dong, Jiang, Xiongying, Wang, Weidong, Li, Dan, Shan, Hong
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Apoptosis Arsenic Biochemistry Gastroenterology Glycoproteins Hepatology Hypoxia Liver cancer Medicine Medicine & Public Health Oncology Original Article Protein expression Transplant Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!